105 related articles for article (PubMed ID: 1998949)
1. Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers.
Moley JF; Brother MB; Wells SA; Spengler BA; Biedler JL; Brodeur GM
Cancer Res; 1991 Mar; 51(6):1596-9. PubMed ID: 1998949
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of RAS point mutations in papillary thyroid carcinoma; a novel mutation at codon 31 of K-RAS.
Cyniak-Magierska A; Brzeziańska E; Januszkiewicz-Caulier J; Jarzab B; Lewiński A
Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):594-9. PubMed ID: 17943694
[TBL] [Abstract][Full Text] [Related]
3. Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma.
Kong XT; Choi SH; Inoue A; Xu F; Chen T; Takita J; Yokota J; Bessho F; Yanagisawa M; Hanada R; Yamamoto K; Hayashi Y
Cancer Res; 1997 Sep; 57(17):3772-8. PubMed ID: 9288786
[TBL] [Abstract][Full Text] [Related]
4. Activated N-ras oncogenes in human neuroblastoma.
Ireland CM
Cancer Res; 1989 Oct; 49(20):5530-3. PubMed ID: 2676145
[TBL] [Abstract][Full Text] [Related]
5. Absence of TP53 alterations in pheochromocytomas and medullary thyroid carcinomas.
Herfarth KK; Wick MR; Marshall HN; Gartner E; Lum S; Moley JF
Genes Chromosomes Cancer; 1997 Sep; 20(1):24-9. PubMed ID: 9290950
[TBL] [Abstract][Full Text] [Related]
6. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
7. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.
Garcia-Rostan G; Zhao H; Camp RL; Pollan M; Herrero A; Pardo J; Wu R; Carcangiu ML; Costa J; Tallini G
J Clin Oncol; 2003 Sep; 21(17):3226-35. PubMed ID: 12947056
[TBL] [Abstract][Full Text] [Related]
8. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
[TBL] [Abstract][Full Text] [Related]
10. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
Jamieson S; Alexiadis M; Fuller PJ
Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971
[TBL] [Abstract][Full Text] [Related]
11. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
[TBL] [Abstract][Full Text] [Related]
12. Oncogene and growth factor expression in MEN 2 and related tumors.
Moley JF; Wallin GK; Brother MB; Kim M; Wells SA; Brodeur GM
Henry Ford Hosp Med J; 1992; 40(3-4):284-8. PubMed ID: 1362425
[TBL] [Abstract][Full Text] [Related]
13. Activation of K-ras by codon 13 mutations in C57BL/6 X C3H F1 mouse tumors induced by exposure to 1,3-butadiene.
Goodrow T; Reynolds S; Maronpot R; Anderson M
Cancer Res; 1990 Aug; 50(15):4818-23. PubMed ID: 2196119
[TBL] [Abstract][Full Text] [Related]
14. Loss of genes on chromosome 22 in medullary thyroid carcinoma and pheochromocytoma.
Takai S; Tateishi H; Nishisho I; Miki T; Motomura K; Miyauchi A; Kato M; Ikeuchi T; Yamamoto K; Okazaki M
Jpn J Cancer Res; 1987 Sep; 78(9):894-8. PubMed ID: 2889715
[TBL] [Abstract][Full Text] [Related]
15. Allele loss on chromosome 10 and point mutation of ras oncogenes are infrequent in tumors of MEN 2A.
Okazaki M; Miya A; Tanaka N; Miki T; Yamamoto M; Motomura K; Miyauchi A; Mori T; Takai S
Henry Ford Hosp Med J; 1989; 37(3-4):112-5. PubMed ID: 2576939
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a transforming N-ras gene in the human hepatoma cell line Hep G2: additional evidence for the importance of c-myc and ras cooperation in hepatocarcinogenesis.
Richards CA; Short SA; Thorgeirsson SS; Huber BE
Cancer Res; 1990 Mar; 50(5):1521-7. PubMed ID: 2154325
[TBL] [Abstract][Full Text] [Related]
17. Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas.
Moul JW; Bishoff JT; Theune SM; Chang EH
J Urol; 1993 Jun; 149(6):1389-94. PubMed ID: 8501773
[TBL] [Abstract][Full Text] [Related]
18. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area.
Shi YF; Zou MJ; Schmidt H; Juhasz F; Stensky V; Robb D; Farid NR
Cancer Res; 1991 May; 51(10):2690-3. PubMed ID: 2021946
[TBL] [Abstract][Full Text] [Related]
19. Mutations in ras oncogenes: rare events in ultraviolet B radiation-induced mouse skin tumorigenesis.
Khan SG; Mohan RR; Katiyar SK; Wood GS; Bickers DR; Mukhtar H; Agarwal R
Mol Carcinog; 1996 Feb; 15(2):96-103. PubMed ID: 8599584
[TBL] [Abstract][Full Text] [Related]
20. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas.
Komuro H; Hayashi Y; Kawamura M; Hayashi K; Kaneko Y; Kamoshita S; Hanada R; Yamamoto K; Hongo T; Yamada M
Cancer Res; 1993 Nov; 53(21):5284-8. PubMed ID: 8221663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
